What are the recommended guidelines for prescribing menopausal hormone therapy (MHT) to healthy perimenopausal women aged 45‑55 with moderate to severe vasomotor or genitourinary symptoms and no contraindications?

Guidelines for Menopausal Hormone Therapy in Perimenopausal Women

For healthy perimenopausal women aged 45-55 with moderate to severe vasomotor or genitourinary symptoms and no contraindications, menopausal hormone therapy (MHT) should be offered as first-line treatment, as it remains the most effective intervention for these symptoms and carries a favorable benefit-risk ratio when initiated within 10 years of menopause onset or before age 60. 1

Key Recommendation Framework

The 2022 North American Menopause Society (NAMS) guidelines provide the most current evidence-based approach 1. MHT is indicated for:

• Moderate to severe vasomotor symptoms (hot flashes, night sweats)
• Genitourinary syndrome of menopause not adequately controlled with over-the-counter therapies
• Prevention of bone loss in women at elevated fracture risk

Critical Distinction: Treatment vs. Prevention

An important caveat: The USPSTF guidelines 2 explicitly recommend against using MHT for primary prevention of chronic conditions (Grade D recommendation). However, these guidelines do not apply to women seeking treatment for menopausal symptoms. The USPSTF specifically states their recommendations fall outside the scope of symptom management 2. This distinction is crucial—your patient with bothersome symptoms is an appropriate candidate for MHT.

Timing Is Everything: The "Window of Opportunity"

The benefit-risk ratio is most favorable when MHT is initiated:

• Within 10 years of menopause onset, OR
• Before age 60 1, 3

For women in this window with moderate-to-severe symptoms, the absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia remain low, while symptom relief is substantial 1. Recent evidence (2025-2026) suggests these chronological limits may be overly restrictive 4, but current guidelines still emphasize this timing window.

Notably, the FDA removed the black box warning on MHT in November 2025, eliminating the mandate for "lowest effective dose for the shortest duration" and incorporating guidance on optimal timing 5. This regulatory shift validates the timing hypothesis and supports individualized dosing.

Formulation Selection Algorithm

For Systemic Symptoms (Vasomotor):

Preferred approach:

• Transdermal estradiol over oral formulations (lower thrombotic and metabolic risk) 1, 6
• Estradiol-based products preferred over conjugated equine estrogens 6

Progestogen requirement:

• Women with intact uterus: Must add progestogen to prevent endometrial hyperplasia
• Women post-hysterectomy: Estrogen alone 1

For Genitourinary Symptoms Only:

First-line: Low-dose vaginal estrogen therapy (estriol, estradiol, or conjugated estrogens) 1, 6

• Does not require systemic progestogen
• Minimal systemic absorption
• Highly effective for urogenital symptoms

Contraindications to Screen For

Absolute contraindications:

• Active or history of breast cancer
• Known or suspected estrogen-dependent malignancy
• Active venous thromboembolism or history of hormone-related VTE
• Active arterial thromboembolic disease (stroke, MI)
• Untreated endometrial hyperplasia
• Active liver disease
• Unexplained vaginal bleeding

Duration of Therapy

Current evidence supports: Continue therapy as long as symptoms persist and benefits outweigh risks 1. The outdated "shortest duration" mandate has been eliminated 5. Periodic reevaluation (annually) is appropriate, but arbitrary discontinuation is not evidence-based for symptomatic women within the favorable timing window.

Common Pitfalls to Avoid

1. Conflating prevention with treatment: The USPSTF recommendations against MHT for chronic disease prevention 2 do not apply to symptomatic women—this is the most common source of confusion in clinical practice.

2. Denying therapy based solely on age: While the 10-year/age-60 window represents optimal timing, emerging evidence suggests these limits may be too restrictive for symptomatic women 4.

3. Using oral estrogen when transdermal is available: Transdermal formulations have superior safety profiles regarding thrombosis and metabolic effects 6.

4. Prescribing systemic therapy for isolated genitourinary symptoms: Low-dose vaginal estrogen is safer and equally effective 1.

Special Consideration: Premature Ovarian Insufficiency

Women with menopause before age 40 should receive MHT regardless of symptoms (unless contraindicated) until at least the average age of natural menopause to prevent long-term health consequences 7.